Erdafitinib in Treating Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With FGFR Mutations (A Pediatric MATCH Treatment Trial)
National Cancer Institute (NCI)
National Cancer Institute (NCI)
Eli Lilly and Company
St. Jude Children's Research Hospital
Pheast Therapeutics
Centre Leon Berard
National Institutes of Health Clinical Center (CC)
National Cancer Institute (NCI)
Washington University School of Medicine
Memorial Sloan Kettering Cancer Center
Eli Lilly and Company
Massachusetts General Hospital
Telix Pharmaceuticals (Innovations) Pty Limited
National Cancer Institute (NCI)
National Cancer Institute (NCI)
National Cancer Institute (NCI)
National Cancer Institute (NCI)
M.D. Anderson Cancer Center
Seattle Children's Hospital
Nationwide Children's Hospital
The New York Proton Center
Hoffmann-La Roche
Stemline Therapeutics, Inc.
Eastern Cooperative Oncology Group
National Institutes of Health Clinical Center (CC)
Hoffmann-La Roche
University of California, San Francisco
Baptist Health South Florida
Neonc Technologies, Inc.
OHSU Knight Cancer Institute
Memorial Sloan Kettering Cancer Center
Dana-Farber Cancer Institute
Cancer Institute and Hospital, Chinese Academy of Medical Sciences
Columbia University
Australian & New Zealand Children's Haematology/Oncology Group
Massachusetts General Hospital
EMD Serono
Alliance for Clinical Trials in Oncology
Abramson Cancer Center at Penn Medicine
St. Jude Children's Research Hospital
Centre Hospitalier Universitaire de la Réunion
Neonc Technologies, Inc.
St. Jude Children's Research Hospital
Blueprint Medicines Corporation
The University of Texas Health Science Center, Houston
Eli Lilly and Company
Incyte Corporation
Reveal Pharmaceuticals Inc.
Jazz Pharmaceuticals
Seattle Children's Hospital
Seattle Children's Hospital